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SCL/TAL1 cooperates with Polycomb RYBP-PRC1
to suppress alternative lineages in blood-fated cells
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During development, it is unclear if lineage-fated cells derive from multilineage-primed
progenitors and whether active mechanisms operate to restrict cell fate. Here we investigate
how mesoderm speciﬁes into blood-fated cells. We document temporally restricted co-
expression of blood (Scl/Tal1), cardiac (Mesp1) and paraxial (Tbx6) lineage-afﬁliated tran-
scription factors in single cells, at the onset of blood speciﬁcation, supporting the existence of
common progenitors. At the same time-restricted stage, absence of SCL results in expansion
of cardiac/paraxial cell populations and increased cardiac/paraxial gene expression, sug-
gesting active suppression of alternative fates. Indeed, SCL normally activates expression of
co-repressor ETO2 and Polycomb-PRC1 subunits (RYBP, PCGF5) and maintains levels of
Polycomb-associated histone marks (H2AK119ub/H3K27me3). Genome-wide analyses
reveal ETO2 and RYBP co-occupy most SCL target genes, including cardiac/paraxial loci.
Reduction of Eto2 or Rybp expression mimics Scl-null cardiac phenotype. Therefore, SCL-
mediated transcriptional repression prevents mis-speciﬁcation of blood-fated cells, estab-
lishing active repression as central to fate determination processes.
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In embryonic development, early cell fate decisions occur atgastrulation when epiblast cells migrate through the primitivestreak (PS) and specify into germ layers1–4. A characteristic of
cells undergoing speciﬁcation is their developmental plasticity, as
revealed by their ability to respond to changing environmental or
intrinsic cues and adopt different fates, suggesting multipotency3.
Cellular identity becomes locked after egression from the PS.
Therefore, acquisition of lineage-speciﬁc features is likely to
coincide with progressive loss of the ability to generate alternative
lineages through restriction of cell potential. Whether emerging
tissue-speciﬁc transcriptional regulators driving lineage speciﬁ-
cation also actively control these restriction processes is unclear.
Speciﬁcation of blood cells from FLK1+ mesodermal pro-
genitors is a model of lineage development. The initial steps of
this process are under control of the transcription factor (TF)
SCL/TAL1, placing it at the apex of the haematopoietic tran-
scriptional hierarchy5,6. Interestingly, absence of SCL not only
leads to complete block in haematopoiesis7,8, but also to expan-
sion of the heart ﬁeld in zebraﬁsh embryos and ectopic cardio-
myocyte production from mouse yolk sac and ES cell-derived
endothelium, revealing latent cardiac potential in blood/endo-
thelial progenitors9–11. Conversely, forced expression of Scl
mRNA expands blood and endothelial tissues at the expense of
myocardial tissues in vivo12 and in vitro13. This highlights a close
developmental relationship between blood and cardiac lineages
and supports the notion of plasticity.
However, it is unclear if common, multilineage-primed blood/
cardiac mesodermal progenitors exist and whether active
repression mechanisms are established in blood-fated cells to
prevent development of the cardiac lineage. Two recent studies
propose contrasting mechanisms. Molecular analyses of ES cell-
derived FLK1+ cells show that SCL occupies a subset of enhan-
cers regulating cardiac-speciﬁc genes, suggesting this makes these
enhancers unavailable for activation by cardiac-speciﬁc TFs11. In
contrast, single cell analyses from mouse Scl−/− embryos failed to
detect increased cardiac gene expression in Scl−/− FLK1+ cells,
questioning the role of SCL in suppressing the cardiac fate14.
However, it is unclear if the two studies were conducted at similar
developmental time points and examined functionally equivalent
FLK1+ cells.
Mechanistically, SCL is both an activating and repressive TF. It
acts within multi-protein complexes containing a core of four
proteins (SCL/E47/LMO2/LDB1) and co-factors/chromatin
remodelling proteins conferring activating (P300/CBP) or
repressive (mSIN3A, ETO2, GFI1B) activities5,15.
Chromatin remodelling proteins, like repressive Polycomb
(PcG) complexes, play critical functions in early development.
PcG complexes control pluripotency and differentiation of
embryonic stem (ES) cells and, in vivo, are required for survival
and organogenesis16. Two PcG complexes (PRC1/PRC2) usually
work in concert. Their activities are associated with distinct his-
tone modiﬁcations: H2AK119 monoubiquitination (H2AK119ub,
PRC1) and H3K27 trimethylation (H3K27me3, PRC2). Several
PcG complexes exist that all contain enzymatic activities (PRC1
ubiquitin ligases; PRC2 methyltransferases), but vary in their
overall composition. PRC1 complexes include ubiquitin ligase
modules (RING1A/1B and PCGF1–6) and CBX or RYBP/YAF2
proteins in a mutually exclusive manner17. PcG complexes
commonly bind CpG islands at gene promoters18.
To get further insight into the mechanisms underlying blood
speciﬁcation, we used murine ES cell differentiation cultures to
follow production of mesoderm-derived blood-fated cells. We
report a series of molecular events that occur over a restricted,
one-day developmental time-window, at the onset of blood spe-
ciﬁcation. We ﬁrst document multi-lineage (blood/cardiac/para-
xial) priming in single mesodermal cells. We then show that
absence of SCL leads to rapid conversion of blood-fated cells into
functional cardiac and paraxial cells, in agreement with the
notion of cellular plasticity. To suppress alternative lineages, SCL
activates expression of select repressors (ETO2 and PRC1
members) and creates a global repressive epigenetic environment,
in parallel to activating blood/endothelial-related genes to pro-
mote haematopoietic speciﬁcation. These processes form the basis
of lineage selection and highlight the prevalence of active tran-
scriptional repression in cell fate choices.
Results
Transient co-expression of distinct lineage-afﬁliated TFs.
Mouse ES cell/embryoid body (EB) differentiation cultures reca-
pitulate major embryonic developmental processes19 (Fig. 1a,
top). Following production of Fgf5+ epiblast-like cells, Brachyury
+ mesoderm develops from day 2.5 (Fig. 1a, right). From day 3,
expression of VEGFA receptor, Flk1, marks the emergence of
mesodermal progenitors at the origin of the endothelial and blood
lineages20. Day 3/3.5 sees robust expression of tissue-speciﬁc
regulators of distinct mesoderm-derived lineages: Scl (haemato-
poietic5), Mesp1 (cardiac21) and Tbx6 (paraxial22) (Fig. 1a, bot-
tom). This stage corresponds to the development of nascent/
posterior mesoderm in the primitive streak of day E7/7.5 mouse
embryos (Supplementary Fig. 1) and marks the onset of lineage
speciﬁcation in the ES/EB model.
To test if multilineage-primed mesodermal progenitors exist,
we asked if Scl, Mesp1 and Tbx6 were co-expressed in the same
cells by single molecule mRNA (smRNA) FISH. We designed
probe libraries for each mRNA species, co-stained day 3 to day
4.5 EB cells and quantitated the number of single mRNA
molecules (foci) in individual cells (Fig. 1b). The average foci
number/cell for each mRNA target (Fig. 1c) followed the
expression pattern of the corresponding mRNA species in cell
populations (Fig. 1a, bottom). When assessing co-expression of
the three markers, we observed triple (Scl/Mesp1/Tbx6) and
double (Scl/Mesp1, Scl/Tbx6) positive cells (Fig. 1d, e, Supple-
mentary Fig. 2a–c). The proportion of these cells amongst Scl-
expressing cells increased from day 3 to day 3.5 (20–35% of total
Scl-positive cells, Fig. 1d), but decreased thereafter (9 and 3% at
days 4 and 4.5, Fig. 1d). Because Mesp1 broad expression in early
gastrulating embryos suggests it could label mesodermal lineages
other than cardiac23,24, data obtained with Mesp1 were conﬁrmed
with another cardiac-deﬁning marker, Gata4 (Supplementary
Fig. 2d). The high proportion of Scl/Mesp1/Gata4-coexpressing
cells amongst day 3.5 Scl/Mesp1-positive cells (87%) validated
Mesp1 as a marker of the cardiac lineage in Scl-expressing cells, at
the developmental timepoint examined. Thus, Scl, Mesp1 and
Tbx6 are co-expressed over a tight developmental time-window.
At a single cell level, the decrease in double and triple positive
cells in day 4/4.5 EBs was accompanied by increased numbers of
Scl-expressing cells (45 and 51% of total EB cells).
We then correlated the level of Scl, Mesp1 and Tbx6 expression
in day 3.5 single cells. High (H) numbers of Scl foci (21–139) were
preferentially associated with no (0–5) or low (6–20 foci)
expression of Mesp1 or Tbx6 (example cell (i), Fig. 1f, g,
Supplementary Fig. 2e), whilst highest numbers of Mesp1
(21–166) or Tbx6 (21–40) foci preferentially occurred in cells
negative (N) for Scl (cells (ii) and (iii), Fig. 1f, g). Similarly, we
never detected co-expression of the three genes at high levels
(Supplementary Fig. 2f).
In conclusion, co-expression of Scl/Mesp1/Tbx6, Scl/Mesp1 and
Scl/Tbx6 preferentially occurs at low mRNA levels in a subset of
Scl-expressing cells at day 3/3.5, consistent with multi-lineage-
priming of distinct mesodermal lineages. Subsequently, as Scl
mRNA levels increase, reﬂecting consolidation of the blood
programme, expression of alternative lineage-speciﬁc regulators is
lost.
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Immunophenotypic conversion of Scl−/− FLK1 positive cells.
Having established the presence of multi-lineage primed cells, we
next investigated how lineage potentials resolve. We studied
blood fate selection in day 3.5 EBs, when 35% of Scl-expressing
cells co-express Mesp1 and/or Tbx6 mRNA. To identify lineage
output, we monitored expression of cell surface markers FLK1
and PDGFRα that separate mesodermal populations with distinct
functional potential25–28 (Fig. 2a). Multiple mesodermal poten-
tials are initially found in the FLK1+PDGFRα+ (double positive,
DP) compartment. FLK1 single positive (F-SP) cells contain lat-
eral plate mesoderm with haematopoietic/endothelial potential
and PDGFRα single positive (P-SP) cells contain paraxial and
cardiac potential.
Flow cytometry staining for FLK1, PDGFRα (Fig. 2bi,
Supplementary Fig. 3a) and SCL (Fig. 2bii) showed that 19%
(±8) of day 3.5 EB cells expressed SCL. 80–93% of SCL-expressing
cells were in the F-SP lateral plate compartment (Fig. 2biii, left
panels). Conversely, 50–62% of the F-SP population expressed
Scl-
positive
cells/
total
EB cells
g
(iii)
Dapi Scl Tbx6 Merge
a
0
M
es
p1
(iii)
f
20 60 1008040
50
100
0
150
140120
200
Scl
(ii)
Number of foci/cell
20
10
30
40
0 Tb
x6
Tbx6 gradient scale
0 40 foci
0
0.1
0.2
0.3
0.4
0.5 Brachyury
0
0.04
0.08
0.12
0.16
0.2 Flk1
0
0.02
0.04
0.06
0.08 Fgf5
Ex
pr
es
sio
n 
le
ve
ls 
re
la
tiv
e 
to
 G
ap
dh
Day 2 4 5 63.532.5
Dapi Mesp1Scl
(ii)
Merge
N L H
e Dapi Mesp1Scl Tbx6
N
eg
at
ive
Tr
ip
le
 p
os
itiv
e
Merge
*
*
*
b d Day 4.5Day 4Day 3.5Day 3
110/583
(19%)
289/734
(39%)
121/319
(45%)
175/343
(51%)
20% 35% 9% 3%
19 foci
0
5
10
15
20
25
Day 3
Cell no. 583
3.5
734
4
319
4.5
343
Scl Mesp1 Tbx6c
Av
er
ag
e 
nu
m
be
r
o
f f
oc
i p
er
 c
el
l
Ex
pr
es
sio
n 
le
ve
ls
re
la
tiv
e 
to
 G
ap
dh
0
0.04
0.08
0.12
0.16
0.2
Mesp1 
0
0.002
0.004
0.006
0.008
0.01
0.012
Tbx6 
0
0.05
0.1
0.15
0.2
0.25
Scl 
Day 2 4 5 63.532.5
Mesodermal
cells
Lineage-fated
cells Blood lineage
Cardiac lineage
Paraxial lineage
ES cells Embryoid bodies (EBs)
Day 2.5/3 Day 3.5/4
Scl/Mesp1/Tbx6  Scl/Tbx6 Scl/Mesp1 Scl 
(i)(i)
2 4 5 63.532.52 4 5 63.532.5
(i)
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07787-6 ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:5375 | https://doi.org/10.1038/s41467-018-07787-6 | www.nature.com/naturecommunications 3
SCL (Fig. 2biii, right panels). To study the fate of SCL-expressing
cells, we FACS-sorted day 3.5 F-SP cells (Supplementary Fig. 3b),
re-aggregated the cells into EBs and, after 24 h, re-analysed FLK1/
PDGFRα expression (Fig. 2c, left, wild-type (WT) panel). 60–70%
of the F-SP cells differentiated into FLK1-PDGFRα- (DN, double
negative) maturing haematopoietic cells29,30. However, about
10% of F-SP cells acquired PDGFRα expression and were detected
in the DP/P-SP compartments. These PDGFRα+ cells may
represent rare cells with higher expression of Mesp1 and Tbx6
than Scl (ScllowMesphi, ScllowTbx6hi and ScllowMesphiTbx6hi -
Supplementary Fig. 2e–f), suggesting there may be competition
between blood and non-blood fates within multilineage-primed
cells, dependent on Scl, Mesp1 and Tbx6 levels. Therefore,
absence of SCL might increase the number of cells adopting
alternative fates.
To test this hypothesis, we isolated F-SP cells from Scl−/− day
3.5 EBs (Fig. 2d) and subjected them to the same re-aggregation
assay employed with WT cells. After 24 h, Scl−/− F-SP cells
exhibited a markedly different immunophenotypic pattern
(Fig. 2c, left, Scl−/− panels). The majority of Scl−/− F-SP cells
acquired PDGFRα expression and were DP or P-SP, consistent
with the hypothesis that they may have acquired non-blood fates.
To validate these observations, we generated two Scl:mCherry
reporter ES cell lines expressing either WT SCL (Scl:mCherry) or
a non-functional form of SCL missing the vital basic helix-loop-
helix domain31 (SclΔ/Δ:mCherry, Supplementary Fig. 3c–f).
Immunophenotyping of day 4.5 EB cells showed that 47.5% of
Scl:mCherry cells and 20.5% of SclΔ/Δ:mCherry were mCherry+
(Fig. 2e, left panels); this difference is likely due to SCL’s positive
transcriptional auto-regulation32. Importantly, a dramatic 76.8%
of SclΔ/Δ:mCherry+ cells expressed PDGFRα (DP/P-SP compart-
ments), as opposed to 8.3% of Scl:mCherry+ cells (Fig. 2e, right
panels), conﬁrming our earlier results.
A key observation from the smRNA FISH experiments was the
tight temporal control of transcriptional priming of blood, cardiac
and paraxial lineages, peaking at day 3.5 and greatly reduced by
day 4.5 (Fig. 1d, Supplementary Fig. 2b). This suggested that cells
could alter mesodermal fates maximally at day 3.5. Indeed, when
compared to day 3.5 Scl−/− F-SP cells, a greatly decreased
number of day 4.5 Scl−/− F-SP cells acquired low level PDGFRα
expression in the re-aggregation assay (Fig. 2c, right panels).
Therefore, temporal restriction of multi-lineage priming corre-
lates with the tight temporal window in which F-SP cells acquire
PDGFRα expression.
Absence of SCL increases adoption of alternative fates. We next
asked if gain in PDGFRα expression in absence of SCL reﬂected
increased numbers of cells adopting non-blood cell fates. We ﬁrst
replated day 3.5 WT and Scl−/− mesodermal populations (P-SP/
DP/F-SP) in conditions promoting cardiac development. Cardiac
cell output was assessed by immunoﬂuorescence staining for
cardiac troponin (cTNT, Fig. 3a) and mRNA analysis
(Tnnt2/Tnni3/Myh6, Fig. 3b). Strikingly, signiﬁcantly more car-
diac cells were detected in the Scl−/− vs. WT P-SP populations,
showing a rapid functional conversion of Scl−/− cells. We con-
ﬁrmed ectopic cardiomyocyte production in vivo from Scl−/−
mouse embryos. Obvious foci of cardiac cTNT+ cells were
detected in day E9.5 Scl−/−, but not WT, yolk sacs (Fig. 3c). Next,
we tested the paraxial potential of WT and Scl−/− cells by re-
plating day 3.5 fractionated or whole EB cells in chondrogenic
conditions. Cultures from Scl−/− P-SP/DP populations exhibited
increased formation of chondrogenic-speciﬁc glycosaminoglycan
clusters (Alcian blue staining, Fig. 3d), and increased expression
of the early chondrogenic marker, Sox933, (Fig. 3e), when com-
pared to WT cells. Similarly, cultures from Scl-/- EB cells showed
more cells positive for COLLAGEN IIA, major downstream target
of Sox934, and increased ColIIa mRNA expression (Fig. 3f).
Increased chondrogenic potential was conﬁrmed in vivo from Scl-
null yolk sacs (Fig. 3g). As controls, haematopoietic cells devel-
oped only from WT, but not Scl−/−, F-SP/DP populations, in
blast colony assays35 (Fig. 3h). Therefore, in absence of SCL,
functional cardiac and paraxial PDGFRα+ populations expand in
day 3.5 EBs.
Finally, to further validate the hypothesis that only Scllow
expressing cells can adopt a non-blood fate, we puriﬁed day 3.5
Scl:mCherrylow and Scl:mCherryhigh cells and tested their devel-
opmental potential in re-aggregation and cardiac assays. As
expected, 24 h after puriﬁcation, the majority of the mCherrylow
cells became mCherryhigh and FLK1/PDGFRα DN, pursuing their
normal hematopoietic differentiation trajectory (Fig. 3i, Supple-
mentary Fig. 3g). Remarkably, however, day 3.5 Scl:mCherrylow,
but not Scl:mCherryhigh, cells generated a PDGFRα-positive
population in the re-aggregation assay (7.9%, Fig. 3i). Conﬁrming
the adoption of alternative fates by cells expressing low levels of
Scl, cTNT-positive cardiomyocytes were exclusively observed
from Scl:mCherrylow cells in cardiac cultures (Fig. 3j). Therefore,
cell fate decisions critically depend on Scl mRNA thresholds.
In conclusion, our data identify a temporally restricted
conversion of day 3.5 Scl−/− F-SP cells into functional cardiac
cells, in line with previous data showing ectopic emergence of
PDGFRα cells with a cardiac expression programme in Scl−/−
yolk sac10. We extend these observations by showing that paraxial
lineage cells are also produced from day 3.5 Scl−/− F-SP cells.
Critically, the tight time-window during which non-blood
lineages are produced in absence of SCL coincides with the
restricted developmental period revealing multilineage-primed
mesodermal cells.
SCL controls expression of transcriptional repressors. We next
deﬁned the molecular mechanism leading to acquisition of non-
blood cell fates in absence of SCL. RNA sequencing revealed 2036
Fig. 1 Scl, Mesp1 and Tbx6 are transiently co-expressed in single cells. a Top, Schematic of ES/EB in vitro differentiation. Right and bottom, RT-qPCR gene
expression analyses from RNA isolated from day 2–6 EB cells (n= 3, mean ± SD). b Example of detection of single mRNA molecules (foci) in a single EB
cell by smRNA FISH. Left, raw image. Right, foci detection (green squares) with ImageJ Macro. c Average number of mRNA molecules/cell determined by
smRNA FISH for Scl, Mesp1 and Tbx6, from day 3 to 4.5 EBs. Cell no.: number of cells analysed at each time point. d Distribution of Scl-positive cells
(Scl/Mesp1/Tbx6, Scl/Tbx6, Scl/Mesp1, Scl-only) in day 3, 3.5, 4, and 4.5 EBs. Total number of EB cells and percentage of Scl-positive cells are indicated for
each timepoint. Cells are considered positive for a marker when harbouring 6 or more foci. e smRNA FISH images showing a negative cell (top panel) and a
cell positive for Scl, Mesp1 and Tbx6 (bottom panel) from day 3.5 EBs. Arrows indicate typical foci for each mRNA species; white star, background signal. f
Signiﬁcant non-linear negative correlation of expression between Scl and Mesp1 and Scl and Tbx6. Each dot represents a cell from day 3.5 EBs (total cells:
734). X-axis, number of Scl foci per cell; Y-axis, Mesp1 foci; Z-axisTbx6 foci. Numbers of Tbx6 foci are also indicated by a grey-red scale. Examples of Scl/
Mesp1 and Scl/Tbx6 negatively correlated cells (i, ii, iii; Fig. 1g) are marked. Correlation coefﬁcients: Scl/Mesp1: −0.2379, p-value < 0.0001, 95% conﬁdence
interval (CI): −0.3117/−0.1612; Scl/Tbx6: −0.1504, p-value < 0.002, 95% CI −0.2274/−0.07151. N, L, H: number of Scl foci/cell (N, negative; L, low (6–20
foci); H, high (21–139 foci)). g smRNA FISH images of representative cells showing Sclhigh/Mesp1low (i, left) and Sclhigh/Tbx6low (i, right), Scllow/Mesp1high
(ii), Scllow/Tbx6high (iii) mRNA foci. Scale bars: 11.3 μm. See also Supplementary Fig. 2
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differentially expressed genes (DEGs) between day 3.5 WT and
Scl−/− FLK1+ cells (Fig. 4a). Consistent with the functional cel-
lular output (Fig. 3a–h), the 1038 genes normally activated by
SCL (upregulated in WT versus Scl−/− cells) were associated with
haematopoietic/endothelial differentiation, as revealed by Gene
Ontology (GO) terms and GSEA analyses (Fig. 4b, examples of
genes in Fig. 4c). In contrast, the 998 genes upregulated in Scl-/-
cells were associated with mesoderm, cardiac and paraxial lineage
development (Fig. 4b, examples of genes in Fig. 4c). Interestingly,
genes encoding transcriptional repressors were also activated in
WT cells (Fig. 4b, c), for example SCL’s partner ETO2
(CBFA2T3)36.
SCL ChIP-seq from day 3.5 WT FLK1+ cells revealed 9836
SCL-bound loci. GO terms associated with the genes nearest to
the peaks were related to haematopoiesis, vasculature and cardiac
development (Fig. 4d). Combining RNA- and ChIP-seq datasets
revealed 778 differentially expressed, SCL-bound loci (hereafter
referred to as SCL direct DEGs, Fig. 4e, Supplementary Data 1).
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Fig. 2 Immunophenotypic conversion of Scl-null FLK1-single positive cells. a Days 3.5/4 ES cell-derived mesodermal populations are functionally deﬁned by
expression of cell surface markers FLK1 and PDGFRα. P-SP, PDGFRα single positive; DP, double positive; F-SP, FLK1 single positive; DN, double negative. b
(i) Distribution of FLK1- and PDGFRα−positive populations in WT day 3.5 EBs. (ii) SCL protein expression in day 3.5 WT EBs (intra-cellular FACS). (iii) Left,
top, distribution of FLK1/PDGFRα-positive cells shown in bi and gated on SCL-positive cells; bottom, mean of 9 independent experiments; Right, top,
distribution of SCL+ cells in each FLK1/PDGFRα compartment. Blue events: SCL+ cells, red events: SCL- cells; bottom, mean of 9 independent experiments.
c Re-aggregation assays. F-SP populations were FACS-sorted from WT and Scl-/- EBs (left panels, day 3.5; right panels, day 4.5), allowed to re-aggregate
for 24 h and analysed for FLK1/PDGFRα expression. The arrows show the different immunophenotypic conversions of WT and Scl-/- cells at day 3.5+ 24 h.
Bottom, mean of two independent experiments. d Top, distribution of FLK1-positive and PDGFRα-positive populations in Scl-/- day 3.5 EBs; bottom,
comparison with WT cells (shown in bi), mean of 4 independent experiments. e Scl:mCherry and SclΔ/Δ:mCherry reporter lines analysed in day 4.5 EBs.
Representative FACS plots of mCherry expression (left), FLK1/PDGFRα expression (middle) and FLK1/PDGFRα plots gated on mCherry-positive cells
(right) are shown. Below, mean of 2 independent experiments. Mean ± SD is shown in b–e; student’s t-test, *p < 0.05, **p < 0.01. Scale bars, 100 μm. See
also Supplementary Fig. 3
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514/778 genes were more highly expressed in WT cells and
related to haematopoiesis and vasculogenesis (Runx1/Fli1, Fig. 4e,
f.) 264/778 genes showed increased expression in Scl−/− cells and
were related to mesoderm, cardiac (Gata6/Mesp1) and paraxial
lineages (Tbx6) (Fig. 4e, f).
We next examined the 100 DEG-associated peaks showing the
strongest SCL binding (greatest number of mapped reads from
ChIP-seq data) (Fig. 4g, Supplementary Data 2). Remarkably, 97
of these peaks were attributed to genes normally activated by SCL.
Whilst 22 peaks were associated to haematopoiesis-related genes
and 10 to endothelium-related genes, 27 were associated with 4
genes encoding blood-related transcriptional repressors: Zfpm1
and Gse1 (Fig. 4f), Eto2 and Runx1t1 (Eto). In addition to these 4
genes, another 7 transcriptional repressors, either expressed in
blood cells (Zfpm2/Gﬁ1/Gﬁ1b/Ikzf1/Izkf2) or members of the
general repressive complex ncPRC1 (Rybp and its partner Pcgf5)
were SCL direct targets (Supplementary Data 1). Of note, the
number of SCL peaks was higher in loci normally activated
(Runx1/Fli1/Zfpm1/Gse1) than on those normally repressed
(Gata6/Mesp1/Tbx6) (Fig. 4f; Wilcoxon rank-sum test conﬁrmed
the difference in peak distribution between all 514 downregulated
and 264 upregulated direct DEGs at p value 5.8 × 10−08). This
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suggests mechanistic differences in SCL-mediated transcriptional
activation versus repression.
In summary, SCL normally activates a blood/endothelial
programme in FLK1+ cells and represses cardiac and paraxial
programmes. Unexpectedly, SCL strongly binds to and activates
expression of genes encoding transcriptional repressors. This
suggests that SCL may suppress cardiac/paraxial programmes in
blood-fated cells through transcriptional activation of repressors.
SCL controls levels of histone marks linked to repression. To
further understand SCL-driven mechanisms of transcriptional
regulation, we surveyed histone marks associated with activated
and repressed genes (H3K27ac/H3K4me3 and H3K27me3/
H2AK119ub, respectively) by quantitative ChIP-seq (ChIP-Rx37)
in mCherry+ cells isolated from Scl:mCherry and SclΔ/Δ:mCherry
day 4 EB cells. H3K27ac, the only mark detected at SCL genomic
binding sites, was analysed at all 9836 SCL ChIP peaks (Fig. 5a)
and on SCL peaks associated to SCL’s 778 direct DEGs (Fig. 5b).
As all these histone modiﬁcations mark promoter regions, we
examined their distribution at transcriptional start sites (TSSs) of
SCL-bound 5512 loci, whole genome TSSs and TSSs of SCL’s 778
direct DEGs (Fig. 5c–f).
H3K27ac was higher at SCL 9836 peaks in WT cells (Scl:
mCherry) than in Scl-null cells (SclΔ/Δ:mCherry) (Fig. 5a),
consistent with SCL’s ability to recruit histone acetyltransferase
P30038. H3K27ac at SCL peaks located in SCL direct DEG
genomic loci was higher in the 514 activated genes compared to
the 264 repressed genes (Fig. 5b, top) in an SCL-dependent
manner (Fig. 5b, bottom). In contrast, H3K27ac and H3K4me3
levels at TSSs of the 5512 loci bound by SCL (of which only 422
are bound by SCL at TSSs) and TSSs genome-wide were SCL-
independent (Fig. 5c). As expected, the level of these two histone
marks was higher at TSSs of the 514 activated genes compared to
the 264 repressed genes and SCL-independent (Fig. 5d). Extend-
ing these observations, we noticed a broad and punctuate
H3K27ac pattern at activated gene loci, not just restricted to
SCL peaks and fully SCL-dependent (Fli1/Mafb, Supplementary
Fig. 4a). SCL-independent H3K4me3 distribution at TSSs was
visualised at both activated (Fli1/Mafb) and repressed
(Gata6/Irx3) genes (Supplementary Fig. 4a, b). In summary,
levels of H3K27 acetylation are higher and SCL-dependent at
SCL’s peaks associated to genes normally activated. At TSSs, both
H3K27ac and H3K4me3 marks are more prominent at genes
normally activated and are SCL-independent.
We next studied histone marks associated with repression,
H3K27me3 and H2AK119ub. In contrast to H3K27ac and
H3K4me3, we observed a striking, global SCL-dependent
reduction of these marks, at TSSs of the 5512 SCL-bound loci
and TSSs genome-wide (Fig. 5e). This reduction was conﬁrmed
by western blot (Fig. 5g, Supplementary Fig. 8a). Furthermore,
whereas SCL-dependent levels of H3K27me3 were just conﬁned
to ~2.5 kb around TSSs genome-wide, SCL-dependent levels of
H2AK119ub extended for large domains (at least 100 kb) either
side of the TSSs (Fig. 5h). Focussing on the 778 SCL direct DEGs,
H3K27me3 levels were higher at TSSs of repressed, rather than
activated, genes (Fig. 5f, top), and showed SCL-dependence at
repressed and, to a lesser extent, activated genes (Fig. 5f, bottom;
Gata6/Irx3/Mafb, Supplementary Fig. 4). Surprisingly, the level of
the H2AK119ub mark did not vary between TSSs of genes
repressed and activated by SCL (Fig. 5f, top), and, in both cases,
was SCL-dependent (Fig. 5f, bottom, Supplementary Fig. 4).
Taken together, these data show that SCL mediates H3K27
acetylation speciﬁcally at SCL-bound cis-regulatory elements of
genes it normally activates. SCL also regulates the level of
repression-associated histone marks, H3K27me3 and
H2AK119ub, not only at TSSs of genes it normally represses
but also at some (H3K27me3) or all (H2AK119ub) genes it
activates. This suggests that inappropriate gene activation may be
restrained by SCL-mediated repressive environment. Regulation
of repression, as surveyed by histone modiﬁcations, constitutes an
important facet of SCL function at the onset of blood
speciﬁcation.
ETO2, RYBP and SCL are functionally linked. To investigate
SCL-regulated active repression of gene expression in mesoderm
patterning, we studied two transcriptional repressors and direct
SCL target genes in day 3.5 FLK1+ cells, ETO2 and RYBP. ETO2 is
a known SCL partner that represses premature megakaryocytic and
erythroid gene activation later in development36,39,40. RYBP,
member of non-canonical PRC1 (ncPRC1) complexes, modulates
H2AK119 ubiquitination levels through stabilisation of RING1B
recruitment and enhancement of its enzymatic activity41–43. Given
the role of PcG complexes in development and the changes in
ubiquitination levels observed in Scl-/- cells, we reasoned that RYBP
may mediate some of SCL-regulated repression mechanisms.
The Eto2 locus was bound by SCL at conserved cis-elements
associated with open chromatin (ATAC-seq) and containing
DNA-binding motifs associated to SCL binding (Fig. 6a,
Supplementary Fig. 5a). Eto2 mRNA expression was initiated at
day 3.5, increased throughout EB differentiation, thus mirroring
Scl’s expression (Figs. 1a, 6b) and was abolished in absence of SCL
(Fig. 6b). Finally, ETO2 was immunoprecipitated from EB cells
with SCL and partners E2A and LMO2 (Fig. 6c, Supplementary
Fig. 9a).
Day 4 ETO2 ChIP-seq analysis showed co-localisation with
SCL at 1949 peaks, which represent ~20% of all SCL peaks and
Fig. 3 Scl-null cells acquire cardiac and paraxial potentials. a–c Cardiac assays. a Day 3.5 WT and Scl-/- P-SP, DP, and F-SP populations were replated in
cardiac condition for 7 days and cTNT (cardiac troponin) expression monitored by immunoﬂuorescence (IF); scale bar, 100 μm. b RT-qPCR analysis of
cardiac gene expression (Tnnt2, Tnni3 and Myh6) relative to Gapdh in cultures shown in a; n= 3–5. c Day E9.5 WT and Scl-/- mouse yolk sacs replated in
cardiac assay for 7 days. IF reveals cardiomyocytes (cTNT, green), endothelium (CD31, red) and nuclei (DAPI, blue). d–g Chondrogenic assays. d Day 3.5
WT and Scl-/- P-SP, DP and F-SP populations were replated in chondrogenic condition for 21 days. Alcian blue staining reveals glycosaminoglycan clusters;
e RT-qPCR analysis of Sox9 expression relative to Gapdh in cultures shown in d, n= 2. f Collagen IIa (ColIIa) expression following culture of day 3.5 WT and
Scl-/- EB cells in chondrogenic condition (left, IF: COLIIA green, DAPI blue; right, RT-qPCR analysis) n= 2. g Alcian blue staining of day 18 chondrogenic
cultures from day E9.5 WT, Scl+/- and Scl-/- mouse yolk sacs. OP9, no yolk sac cells. c, g Number of embryos presenting the phenotype shown is indicated
for each genotype. h Blast colony assay showing number of endothelial/haematopoietic colonies obtained from day 3.5 WT and Scl-/- puriﬁed mesodermal
populations (P-SP, DP, F-SP); n= 3. i Left: day 3.5 Scl:mCherry WT cells were FACS-sorted according to the level of mCherry (and therefore SCL)
expression into low and high fractions. Right: mCherryhigh and mCherrylow cells were re-aggregated for 24 h, and mCherry (left) and FLK1/PDGFRα (right)
expression re-assessed. Note that only the day 3.5 mCherrylow fraction produced a PDFGRα+ population (bottom right panel, orange events). At day 3.5+
24 h, the majority of the PDGFRα+ cells have lost mCherry expression (bottom left panel, orange events). j Day 3.5 Scl:mCherryhigh and Scl:mCherrylow
FACS-sorted cells were replated in cardiac assay. IF reveals cardiomyocytes (cTNT, green), endothelium (CD31, red) and nuclei (DAPI, blue). Mean ± SD is
shown (b), (e), (f), (h); student’s t-test, *p < 0.05, **p < 0.01. Scale bars, 100 μm. See also Supplementary Fig. 3
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Fig. 4 SCL controls distinct gene regulatory networks in day 3.5 FLK1+ cells. a Hierarchical clustering of RNA-seq data from day 3.5 WT and Scl-/- FLK1+ EB
cells. b Gene ontology (GO) processes associated to differentially expressed genes (DEGs) (PANTHER and GSEA analyses). c Heatmap showing selected
DEGs associated to GO processes identiﬁed in b. In bold, transcriptional regulators. d The top more signiﬁcant GO biological processes associated to SCL-
bound loci (GREAT analysis). e Integration of SCL ChIP-seq and RNA-seq data reveals 778 SCL direct differentially expressed target genes. Below, GO
terms attributed to DEG-associated peaks (GREAT analysis). f Left, SCL ChIP-seq tracks of selected direct DEGs; FC=NS, fold-change in expression in
Scl-/- cells is not signiﬁcant (RNA-seq data). Tbx6 locus: the SCL peak was attributed to Tbx6, the closet DEG. Right, RT-qPCR gene expression analysis
relative to Gapdh from WT and Scl-/- day 3.5 FLK1+ cells. n= 3, mean ± SD; student’s t-test, *p < 0.05, **p < 0.01. Colour code, same as in c. g Biological
functions attributed to the 100 strongest DEG-associated SCL ChIP-seq peaks. In brackets, numbers of genes in each category. See also Supplementary
Data 1, 2
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60% of all ETO2 peaks (Fig. 6d, Supplementary Fig. 6a). The
biological processes related to the genes associated to these 1949
peaks were enriched for blood, vascular, cardiac and muscle
development (Supplementary Fig. 6b). We then considered the
1725 gene loci co-occupied by SCL and ETO2. These corre-
sponded to 31% of SCL-bound genes (1725/5512) and 79% of
ETO2-bound genes (1725/2186) (Fig. 6e). These genes contained
352 out of SCL’s 778 direct DEGs (45%). The strength of SCL and
ETO2 binding across these 352 DEGs was the same for both
proteins: higher in the genes activated by SCL vs. those repressed
(Supplementary Fig. 6c). Therefore, SCL and ETO2 often co-
localise on activated and repressed genes and most likely co-
operate in multi-protein complexes.
Similarly, SCL binding was detected at the loci encoding Rybp
and its partner Pcgf5, in areas associated with open chromatin
and SCL-binding DNA motifs (Fig. 6f, Supplementary Fig. 5b).
Strikingly, expression of Rybp and Pcgf5 was signiﬁcantly
downregulated in days 3.5/4 Scl−/− EB cells (Fig. 6g), corre-
sponding to the narrow time-window of transcriptional co-
priming of blood/cardiac/paraxial lineages and developmental
plasticity of F-SP cells (Figs. 1d, 2c). None of the other members
of PRC1/PRC2 complexes we examined, including enzymes
responsible for deposition of PcG-associated histone marks
(Ring1a/1b, Ezh1/2), or members of the KAT and TrxG activating
complexes, were direct targets of SCL (Fig. 6f, g, Supplementary
Fig. 7), highlighting the unique relationship between SCL and
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Fig. 5 SCL loss-of-function affects the epigenetic landscape of blood-fated progenitors. a, c, e Distribution plots of normalised histone mark ChIP-seq
signals in mCherry+ cells puriﬁed from Scl:mCherry and SclΔ/Δ:mCherry day 4 EBs. Signals are sorted on SCL ChIP-seq peaks (a H3K27ac only), TSSs of SCL-
bound 5512 genes and TSSs across the whole genome, ±2.5 kb, (c activation associated-marks H3K27ac and H3K4me3; e repression associated-marks
H3K27me3 and H2AK119ub). b, d, f Distribution plots of normalised histone mark ChIP-seq signals in mCherry+ cells puriﬁed from Scl:mCherry and SclΔ/Δ:
mCherry day 4 EBs on SCL direct DEGs (514 activated genes (red) and 264 repressed genes (blue)). Signals are sorted on SCL ChIP-seq peaks associated
to SCL direct DEGs (b H3K27ac only) and TSSs of SCL direct DEGs, ± 2.5 kb (d, activation associated-marks; f repression associated-marks). Top, Scl:
mCherry EB cells; bottom, Scl:mCherry and SclΔ/Δ:mCherry EB cells. g Western blot analysis of H3K27me3 and H2AK119ub levels in mCherry+ cells puriﬁed
from Scl:mCherry and SclΔ/Δ:mCherry day 4 EBs. H2A, loading control. Relative levels of each histone mark over H2A in mutant versus control cells are
indicated. n= 2. h Distribution plots of normalised H3K27me3 and H2AK119ub ChIP-seq signals in mCherry+ cells puriﬁed from Scl:mCherry and SclΔ/Δ:
mCherry day 4 EBs. Signals are sorted on TSSs across the whole genome; top, ±10 kb, bottom, ±100 kb. See also Supplementary Figs. 4, 8
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RYBP/PCGF5. Finally, in contrast to the Eto2 locus, binding of
SCL to Rybp and Pcgf5 loci was not seen in maturing blood cells
(foetal liver pro-erythroblasts)44 (Supplementary Fig. 5a, b),
suggesting speciﬁc requirements for these two repressors during
early blood speciﬁcation processes.
Immunoprecipitation (IP) of EB nuclear extracts with either
RYBP or RING1B antibodies co-puriﬁed the SCL/E2A/LMO2
complex (Fig. 6h, bottom, Supplementary Fig. 9b, c). Reciprocal
IP using SCL antibodies recovered RING1B but not RYBP
(Fig. 6h, top, Supplementary Fig. 9a), suggesting that only a small
fraction of RING1B/RYBP is complexed with SCL. Indeed, SCL
and RYBP binding co-localised at only 911 peaks by day 3.5/4
ChIP-seq analyses, which represents 9% of SCL peaks and 4% of
RYBP peaks (Fig. 6i, Supplementary Fig. 6d). Interestingly, GO
analysis of the biological processes associated with the loci related
to the 911 peaks showed enrichment for blood, cardiac and
muscle development (Supplementary Fig. 6e). Finally, 4075 gene
loci showed SCL and RYBP co-occupancy (where binding does
not necessarily co-localise), corresponding to 73% of SCL-bound
genes and 31% of RYBP-bound genes (Fig. 6j). These genes
contained 710 out of 778 (91%) SCL direct DEGs, suggesting co-
regulation by SCL and RYBP (Fig. 6j).
In conclusion, ETO2’s expression entirely relies on SCL
throughout EB differentiation and full expression of RYBP and
PCGF5 requires SCL within a narrow developmental window.
ETO2 and RYBP interact with SCL. When considering gene loci,
ETO2 co-occupies nearly half and RYBP the majority of SCL
direct DEGs.
Genome-wide interaction of SCL, ETO2 and RYBP with
chromatin. To explore the shared and distinct gene sets regulated
by SCL, ETO2 and RYBP, we examined the binding of these three
regulators at SCL’s 778 direct DEGs. This deﬁned 4 gene
categories:
(1) 330/778 gene loci (42%) were co-occupied by SCL/ETO2/
RYBP (Fig. 6k, Supplementary Data 3). 262/330 genes were
activated by SCL and required for blood (Scl/Fli1/Runx1/
Gata2) and endothelial (Sox17/Efnb2/Erg) development,
haematopoiesis and erythropoiesis (Mafb/Gypc/Ache/Epor),
and encoded transcriptional repressors (Gﬁ1b/Eto2/Ikzf1/
Runx1t1) (Fig. 6k, l). Sixty-eight genes were repressed by
SCL and involved in differentiation of cardiac (Gata4/
Gata6/Wnt5a/Foxc1) and paraxial (Irx3/Six2/Ctgf) fates
(Fig. 6k, l).
(2) 380 genes (49%) co-occupied by SCL/RYBP, but not ETO2,
were equally activated and repressed (Fig. 6k, l). Activated
genes were mainly associated with cell adhesion/migration
(Cdh5/Itgb3/Cdh22/Lamc1) and repressed genes with early
developmental/mesoderm speciﬁcation (Gsc/Mixl1/Etv2/T)
(Fig. 6k, l).
(3) 22 genes (3%) co-bound by SCL/ETO2, but not RYBP, were
mainly activated but functionally required at later stages of
haematopoietic differentiation (Gata1/Nfe2) (Fig. 6k, l).
(4) 46 genes (6%) were only bound by SCL, equally activated or
repressed and mainly involved in metabolism (activated
genes) and inﬂammation (repressed genes) (Fig. 6k, l).
In conclusion, SCL and these repressors bind to overlapping
and distinct functional categories of activated and repressed target
genes.
Loss of Eto2 and Rybp phenocopies SCL-null cardiac pheno-
type. Given the aggregate molecular and biochemical data that
SCL, ETO2 and RYBP could function in concert at the time of
blood speciﬁcation, we asked if loss of ETO2 or RYBP could
phenocopy loss of SCL in developing EBs (Fig. 7a). We ﬁrst
knocked down expression of Eto2 and Rybp RNA and protein by
siRNA, by 40–70%, at day 3.5 (siEto2 and siRybp, Fig. 7b, c,
Supplementary Fig. 8b). The level of reduction of Rybp mimicked
that seen in absence of SCL during the window of mesodermal
lineage speciﬁcation (Fig. 6g) and, strikingly, led to decreased
levels of H2AK119ub similar to that observed in SclΔ/Δ:mCherry
cells (Figs. 5g, 7c Supplementary Fig. 8c). Importantly, Eto2 and
Rybp knock-down cells produced a 4–6-fold increase in cTNT-
positive cells in cardiac assays, similar to that observed in
absence of SCL (Fig. 7d, e). Similarly, induction of Rybp deletion
in Rybpﬂ/ﬂ:Cre-ERT245 EBs resulted in complete loss of Rybp
expression (Fig. 7f) and expansion of cTNT-positive cardiac cells
(Fig. 7g). Importantly, reduction of Eto2 and Rybp expression did
not alter blood lineage speciﬁcation assayed by blast colony assays
(Fig. 7h).
To directly test the function of H2AK119ub in cardiac
development, we treated EBs with PRC1 ubiquitin ligase inhibitor
PRT416546. This achieved up to 84% decrease in ubiquitination
levels (Fig. 7i, Supplementary Fig. 8d) and led to increased cardiac
output, as judged by cTNT staining and Tnnt2 mRNA expression
(Fig. 7j), suggesting that H2AK119 ubiquitination mediates the
cardiac phenotype observed from Rybp knock-down and Scl-null
cells.
Finally, we asked if reduction in H3K27me3 could have a
similar effect. We treated EBs with PRC2 inhibitor UNC1999
targeting EZH1/2 function47, to achieve near complete loss of
H3K27me3 at day 3.5 (Fig. 7k, Supplementary Fig. 8e). Here,
there was no increase in cardiac output assayed by cTNT staining
and Tnnt2 mRNA expression (Fig. 7l).
Fig. 6 Genome-wide binding of SCL, ETO2 and RYBP in FLK1+ cells. a SCL ChIP-seq track of Eto2 locus in day 3.5 FLK1+ EB cells. Blue arrows, SCL peaks
associated to Eto2; red rectangles, ATAC peaks; green rectangles, SCL-bound cis-elements further detailed in Supplementary Fig. 5. b RT-qPCR analyses of
Eto2 mRNA expression from WT and Scl-/- EB differentiation kinetics (day 2–day 6) relative to Gapdh. n= 3–5, mean ± SD; student’s t-test *p < 0.05. c
Western blot analysis of day 4.5 WT EB nuclear extracts immunoprecipitated (IP) with anti-SCL antibodies. Members of SCL complex are detected as
indicated. n= 3. d Overlap between SCL and ETO2 ChIP-seq peaks. e Overlap between SCL-bound and ETO2-bound genes. 352 of these are SCL direct
DEGs. f SCL ChIP-seq track of Rybp, Pcgf5 and Ring1b loci in day 3.5 FLK1+ EB cells. Blue arrows, SCL peaks associated to the genes; red rectangles, ATAC
peaks; green rectangles, SCL-bound cis-elements further detailed in Supplementary Fig. 5. g RT-qPCR analyses of Rybp, Pcgf5 and Ring1b mRNA expression
fromWT and Scl-/- EB differentiation kinetics (day 2–day 6) relative to Gapdh. n= 3–5, mean ± SD; student’s t-test *p < 0.05. hWestern blot analysis of day
4.5 WT EB nuclear extracts immunoprecipitated (IP) with anti-SCL antibodies (top), -RYBP (bottom, left) and -RING1B (bottom, right) antibodies.
Members of PRC1 complex (RING1B, RYBP) and SCL complex (LMO2, ETO2) are detected as indicated. Asterisk (*) indicates heavy or light IgG chain.
White arrow indicates SCL band in RING1B IP. i Overlap between SCL and RYBP ChIP-seq peaks. j Overlap between SCL-bound and RYBP-bound genes.
Seven hundred and ten of these are SCL direct DEGs. k Overlap between SCL-bound, ETO2-bound, and RYBP-bound 778 SCL direct DEGs. Number and
representative examples of SCL direct target genes in the four categories deﬁned by SCL, ETO2, and RYBP binding are shown. l UCSC tracks showing SCL,
ETO2 and RYBP binding on examples of activated and repressed SCL direct DEGs in the four categories deﬁned by SCL, ETO2, and RYBP binding. See also
Supplementary Figs. 4–6 and 9, Supplementary Data 3
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Altogether, these data suggest speciﬁc roles for ETO2 and
RYBP and, by association, the PRC1 complex, most likely
through H2AK119 ubiquitination, to suppress alternative fates in
FLK1+ cells in collaboration with SCL.
Discussion
We have studied how lineage commitment is executed during
development by focusing on how ES cell-derived FLK1+ meso-
dermal cells segregate into the blood lineage and suppress
alternative cardiac and paraxial lineage programmes. We show
that, at a narrowly deﬁned time-point, a single TF, SCL, not only
promotes haemopoiesis in FLK1+ cells, but concurrently sup-
presses mis-speciﬁcation of these cells to alternative lineages
(Fig. 8). A series of genome-wide molecular and biochemical
studies demonstrates that SCL represses alternative gene expres-
sion in collaboration with ETO2 and the PRC1 complex at the
precise time-point when multi-lineage transcriptional priming
and cellular plasticity are detected. Whether this occurs in FLK1
+SCL+ haematopoietic progenitors giving rise to primitive and/
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or deﬁnitive blood cells is not known as, to date, these two types
of progenitors cannot be distinguished immunophenotypically or
by gene expression.
Our ﬁndings have broad implications for our understanding of
lineage determination. First, low level co-expression of Scl, Mesp1
and Tbx6 (required to specify blood, cardiac and paraxial linea-
ges, respectively) conﬁrms multi-lineage priming and suggests
that progenitors can potentially adopt multiple fates. Existence of
multilineage-primed cells agrees with studies showing that epi-
blast cells exhibit multipotency48 and with observations of
“transcriptional noise” in day E6.5 mouse epiblast cells49.
Importantly, multi-lineage priming needs to be distinguished
from multi-lineage potency. Even though Mesp1 and Tbx6 are co-
expressed with Scl in blood-fated FLK1+ cells, and, in absence of
SCL, these cells can make cardiac and paraxial lineages, it is
unclear if these cells are multi-potent at a clonal level in steady
state, as multi-potency may only manifest in perturbed circum-
stances. One approach to address these open questions is to
conduct in vivo fate tracing studies at appropriate developmental
stages. This will characterise the extent of multi-potency and
establish developmental relationships between mesodermal
lineages.
Second, our data reveal the tight developmental window
determining functional plasticity. Multi-lineage primed cells were
most abundant in day 3.5 EBs and dramatically reduced at day
4.5. FLK1+ Scl−/− cells gave rise to PDGFRα+ cardiac/paraxial
cells at day 3.5, but not at day 4.5. Finally, SCL activated Rybp and
Pcgf5 expression at days 3.5/4 only. In wild-type cells, plasticity is
detected in cells expressing low levels of Scl, as only Scl:mCher-
rylow cells can adopt a cardiac fate at day 3.5, likely to be elicited
by higher Mesp1 levels. This supports the notion of threshold-
dependent fate determination, as recently reported for the TF
ETV2 in hemangiogenic fate speciﬁcation50. At earlier stages of
development, the trophectoderm and the inner cell mass also
exhibit time-restricted plasticity51,52. This is believed to establish
ﬂexible gene regulatory networks based on heterogeneity of gene
expression53. Plasticity may therefore be a general property of
cells undergoing lineage determination.
Third, our study reveals the importance of active repression of
alternate fates in lineage-fated cells. To the best of our knowledge,
we provide the ﬁrst example of a single lineage-speciﬁc TF (SCL)
directly regulating expression of PcG members during develop-
ment. In so doing, SCL regulates PRC1 function, as shown by
SCL-mediated global H2AK119 ubiquitination. Though PRC1
exhibits repressive roles during early embryonic
development41,45, somatic cell reprogramming54 and haemato-
poietic development55, a function in lineage selection in germ
layers has not been previously reported.
SCL activates expression of two speciﬁc PRC1 members, RYBP
and PCGF5, both necessary for the function of ubiquitin ligase
RING1B and full H2AK119 ubiquitination levels42,56. Thus, it is
unsurprising that ubiquitination levels depend on SCL in blood-
fated cells. Whilst our biochemical data indicate interaction
between RYBP and SCL and co-localisation on a few genes, the
mechanisms controlling RYBP recruitment and H2AK119ub
deposition for most genes remain unclear. Interestingly, RYBP-
PRC1 target genes are usually expressed at higher levels than
targets of canonical PRC1 complexes42. This suggests that
ncPRC1 may cause incomplete gene expression silencing, thus
permitting low-level gene expression and allowing lineage-fated
cells to retain plasticity. Thereafter, ncPRC1 complexes could be
replaced by more potent complexes, causing irreversible gene
silencing and loss of plasticity.
Our work also reveals a complex pattern of gene regulation by
SCL, ETO2 and RYBP. Indeed, ChIP-seq shows locus-speciﬁc
binding of ETO2 and RYBP on SCL’s 778 activated and repressed
genes. Why would co-repressors bind to genes normally acti-
vated? One possibility is that co-repressors ﬁnely modulate gene
expression levels, rather than simply repressing gene expres-
sion57. This transcriptional ﬂexibility could allow for rapid
Multi-lineage priming
Fate consolidation
Repressive environment
Scl
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Tbx6
FLK1+PDGFRα–
blood-fated cells 
Rybp, Pcgf5, Eto2
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Fig. 8 Model of SCL’s functions in blood lineage speciﬁcation. Single
mesodermal cells co-express blood (Scl), cardiac (Mesp1) and paraxial
(Tbx6)-afﬁliated transcriptional regulators at low levels, establishing multi-
lineage priming and cellular plasticity. As differentiation progresses, Scl
levels increase in FLK1+PDGFRα– cells. SCL establishes a global repressive
environment by activating potent transcriptional repressors (Rybp/Pcgf5/
Eto2) and ensuring genome-wide, high H2AK119Ub levels. This leads to
decreased Mesp1 and Tbx6 levels and repression of alternative fates.
Activation of blood/endothelial gene expression programmes together with
decreased plasticity allows consolidation of the blood fate and speciﬁcation
of the hematopoietic lineage
Fig. 7 Rybp and Eto2 knock-down phenocopies Scl-/- cardiac phenotype. a Outline of functional assays. b–e siRNA-mediated Eto2 (siEto2) and Rybp (siRybp)
knock-down in day 3.5 EBs. b qRT-PCR analysis of Eto2 and RybpmRNA levels. Analysis from day 3.5 WT and Scl-/- EB cells is shown for comparison. siNeg,
siRNA negative control; n= 4. c Western blot analysis of RYBP and H2AK119ub levels. mSIN3A and H2A, loading controls; n= 2. d, e Day 3.5 WT, Scl-/-,
siEto2-treated, siRybp-treated and siNeg-treated EB cells were plated in cardiac condition. cTNT expression was monitored at day 7 by IF (d, top) and intra-
cellular FACS (d, bottom). Quantitation of FACS data from Scl-/-, siEto2- and siRybp-treated cultures is shown as Scl-/-/WT, siEto2/siNeg and siRybp/siNeg
ratios (e); n= 2. Scale bars, 100 μm. f qRT-PCR analysis of Rybp expression in day 3.5 untreated (UN), tamoxifen- (TAM) and ethanol (EtOH)-treated
CreERT2:Rybpﬂ/ﬂ EBs; n= 2. g Day 3.5 untreated, EtOH-treated or TAM-treated CreERT2:Rybpﬂ/ﬂ cells were plated in cardiac condition. cTNT expression
was assessed at day 7 by IF (green, left) and qRT-PCR analysis (Tnnt2, shown as TAM/ETOH fold increase, right). Scale bar, 100 μm. n= 2. h Day 3.5 WT,
Scl-/-, siEto2-treated, siRybp-treated and siNeg-treated EB cells were plated in blast colony assay; n= 2. iWestern blot analysis of H2AK119ub in day 3.5 EB
cells treated with increasing concentrations of PRC1 inhibitor (PRT4165). UNT, untreated; αTubulin and H2A, loading controls, n= 2. j PRC1 inhibitor or
DMSO-treated EBs were plated in cardiac assay, and cTNT expression assessed at day 7 by IF (green, top), FACS (bottom) and qRT-PCR (Tnnt2, right); n
= 3. k Western blot analysis of H3K27me3 in day 3.5 EB cells treated with increasing concentrations of PRC2 inhibitor or analogue. mSIN3A, loading
control, n= 2. l Day 3.5 EB cells treated with PRC2 inhibitor or analogue were plated in cardiac condition, and cTNT expression assessed at day 7 by IF
(green, left) and qRT-PCR (Tnnt2, right). n= 2. Scale bars, 100 μm. Mean ± SD is shown in b, f, h, j, l; mean of ratios of mutant samples versus controls ± SD
is shown in e, g; student’s t-test, *p < 0.05. See also Supplementary Fig. 8
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changes in transcription patterns to adapt to changing environ-
ments, and underlies cellular plasticity and transcriptional
priming. What mechanisms dictate whether a gene is bound by
any combination of SCL/ETO2/RYBP and whether it is activated
or repressed remain important questions. Detailed analyses of
speciﬁc gene loci are required.
Finally, our work highlights some of the relationships between
histone marks, TF/co-factor binding and gene expression.
Although the signiﬁcance of SCL-dependent H2AK119 ubiquiti-
nation over extended genomic regions remains unclear, this
observation is reminiscent of the wide “blanket” of Polycomb
recruitment on the inactive X chromosome58, a paradigm of
transcriptional repression. Based on the hierarchical model that
PRC1 recruits PRC218, H2AK119Ub marks may facilitate
recruitment of PRC2 and maintain high levels of H3K27me3 at
genes normally repressed in lowly acetylated chromatin. Gen-
ome-wide, high levels of ubiquitination also suggest that the
default transcriptional state may be gene expression silencing. It is
noteworthy that genes activated by SCL usually harbour multiple
SCL binding sites, whilst repressed genes show much fewer
binding events. Multiple SCL occupancy sites may be required to
robustly recruit activating epigenetic complexes to overcome a
globally repressive environment.
In conclusion, this study unveils the importance of transcrip-
tional repression by a single tissue-speciﬁc regulator in multi-
lineage primed cells and over tightly deﬁned developmental
windows during which lineage-speciﬁc gene expression pro-
grammes are initiated. Complex, gene-speciﬁc patterns of tran-
scriptional regulation promote and repress lineage-afﬁliated gene
expression to allow single lineage selection. These mechanisms
are likely to be shared by other lineage-speciﬁc regulators in
development and differentiation.
Methods
Single molecule RNA FISH (smRNA FISH). smRNA FISH was performed as
described59, with some alterations. In brief, oligonucleotide libraries (18–20
nucleotide-long) were designed using Stellaris Probe Designer to bind mainly to the
ORF of each target mRNA (35 oligos for Scl, 29 oligos for Mesp1 and 38 oligos for
Tbx6) and synthesised with 3′ 3NHC6 modiﬁcations. They were pooled and
labelled with Alexa NHS esters using Alexa-488 (Mesp1—Lifetech A20000), Alexa-
594 (Scl—Lifetech A37572) or Alexa-647 (Tbx6 and Gata4—Lifetech A37573) as
described by the manufacturer. Only probes with a frequency of incorporation of
>90% (calculated with Geneﬂow nanophotometer) were used.
100,000 EB cells were adhered to poly-L-Lysine-pre-coated coverslips (20 min,
37 °C). Cells were ﬁxed in 4% Paraformaldehyde (PFA, 20 min, room temperature
-RTo), washed with PBS and permeabilised with 70% EtOH (overnight (o/n), 4 °C).
After rehydration in wash buffer (2× SSC, 10% Formamide), cells were incubated
with probes at a ﬁnal concentration of 1 ng/μl in hybridisation buffer (2× SSC, 10%
Formamide, 10% Dextran Sulphate, 1 mg ml−1 tRNA, 2 mM RNase inhibitor (RVC
complex, NEB), 0.2 mg ml−1 BSA) in a humidity chamber (o/n), 30 °C). Cells were
then washed twice in wash buffer (30 min, 30 °C) and once in wash buffer+DAPI
0.5 μg ml−1 (Sigma, cat# D9542) 30 min, 30 °C. Coverslips were mounted with
Prolong Gold, which was allowed to polymerise o/n at RTo, in the dark, before
imaging with a Delta Vision wideﬁeld microscope using a 100x oil objective.
Microscopy and data analysis. To avoid bleaching, smRNA FISH images were
focused and taken based on DAPI stain only. For each image, a Z-stack of 53
images was acquired for all channels (DAPI, Alexa-488, Alexa-594 and Alexa-647).
Image volumes were analysed using a Fiji/ImageJ macro script that automated the
analysis (available upon request). Firstly, image volumes were Z-maximum-
projected through a sub-range of the original slices; the sub-range was pre-chosen
to best encapsulate the signal containing range of the cells within a dataset. Next,
background ﬂuorescence in the DAPI channel was removed from images by
smoothing a copy of the maximum-projected image with a coarse Gaussian ﬁlter
(sigma= 80) and subtracting this from the unsmoothed image. The ﬁltered image
was then thresholded to extract the nuclear regions. From this binary image, a
Voronoi ﬁlter was applied to evenly split the image into regions based on the
location of the nuclear centres. Each region was then assigned to the nucleus it
encapsulated. Within each nuclei-associated region, the corresponding cell auto-
ﬂuorescence in the 488 nm channel was used to identify the cell. Segmentation was
performed by thresholding the cellular ﬂuorescence using an Otsu algorithm to
convert the image into a binary representation, and then, using the “Watershed”
algorithm, to split any larger objects. These cellular regions were then dissected
using the Voronoi regions to split them up based on the distribution of nuclear
centres. Regions of ﬂuorescence within the thresholded auto-ﬂuorescence channel
and containing a corresponding DAPI signal were retained for further analysis; all
other areas were discarded. This methodology provided an accurate means of
obtaining cell regions even if more than one cell were touching and also removed
artifactual stained non-cellular areas. Finally, within each cell, the channels con-
taining the foci (Mesp1-A448, Scl-A594 or Tbx6-A647) were processed sequen-
tially. All channels were smoothed with a Gaussian ﬁlter (sigma= 0.5) to reduce
the impact of signal noise. Following this processing step, the signal intensities were
identiﬁed and measured. The foci locations were identiﬁed using the ImageJ “Find
Maxima” function with a simple ﬁltering step to remove maxima that were too
large to be foci (>40 total pixel area). To avoid false positives, a speciﬁc point of cut
off for positivity of 6 foci per cell was chosen after performing smRNA FISH on
cells derived from ES cells knocked-out for the mRNAs of interest. Within these
cells, the number of foci and also the average intensity level was measured from
regions (5 × 5 pixel) centred on each foci. In addition, as a comparison, the
intensity was also measured in regions surrounding the foci to give an idea of the
background noise in these samples. These regions were selected by taking the
coordinates of each true foci and then randomly perturbing the coordinates to ﬁnd
a region nearby (within 10 pixels) which did not overlap with any of the true foci
locations. Data were exported to Excel for subsequent analysis and statistical
testing.
Images shown in Fig. 1 and Supplementary Fig. 2 are maximum Z-stack
projections of ﬂuorescence images spanning the extent of the cells, in inverted
black/white for Scl, Mesp1 and Tbx6. Within each subﬁgure, images from the same
channel were adjusted equally, for direct comparison. Before compilation of
experiments, a Stratiﬁed Kruskal–Wallis test was performed to check for signiﬁcant
differences, and none were found. To test for signiﬁcant increases or decreases in
cellular sub-types, a two-tailed Fisher’s exact test was applied.
Embryonic stem (ES) cell culture and differentiation. Mouse ES cells (J1 wild-
type, Scl-/-8, Scl:mCherry, Rybpﬂ/ﬂ;Cre-ERT2—generous gift from M. Vidal45) were
maintained in DMEM high glucose supplemented with 15% batch-selected fetal
bovine serum (FBS), 2 mM glutamine (Gibco/BRL), 2% LIF-conditioned medium
and 1.5 × 10−4 M MTG. Twenty-four hours prior to differentiation, cells were
passaged in LIF-containing IMDM medium. On the day of differentiation,
50,000–80,000 cells were seeded in 100 mm Petri Grade dishes in IMDM medium
supplemented with 15% batch-selected FBS, 2 mM glutamine, 300 μg/ml trans-
ferrin (Roche, cat# 10652202001), 4.7 × 10−4 M MTG (1-Thiolglycerol, Sigma,
M6145), and 50 μg ml−1 ascorbic acid. Cultures were maintained in a humidiﬁed
incubator in 5% CO2/air at 37 °C.
Scl:mCherry cell lines. gRNAs (sequences are shown in Supplementary Table 1)
were inserted into GFP-expressing pX458 or a derivative of pX330 (Addgene), by
BbsI digestion and ligation. ES cells were transfected with gRNAs and a homology
donor (sequences available upon request) using Nucleofector 2b (Lonza) with
programme A-013. 48hrs after transfection, single GFP-positive cells were sorted,
clones expanded and checked for insertion by Sanger sequencing. The heterozygote
Scl:mCherry cell line was generated from WT J1 cells using mCherry_gRNAs, and
harbours the mCherry insertion on one allele. The SclΔ/Δ:mCherry cell line was
engineered from the Scl:mCherry cell line with mCherryΔgRNA1 and mCher-
ryΔgRNA2, and is homozygous for deletion of the bHLH domain.
siRNA and inhibitors. siRNAs—Day 2 WT EBs were transfected with 50 nM
siRNA against Eto2 (Darmacon, siGenome mouse Cbfa2t3 SMART pool, M-
042769) or Rybp (Darmacon, siGenome mouse Rybp SMART pool, M-042769) or
with siRNA control (Darmacon, siGenome control pool, non-targeting, D-001206)
using lipofectamine RNAimax (LifeTechnologies, cat#13778) following the man-
ufacturer’s recommendations. At day 3.5, transfected cells were dissociated and
replated in cardiac or blast colony assay. Gene expression was assessed by qRT-
PCR at days 3.5 and 4.5.
Increasing concentrations PRC1 and PRC2 inhibitors were added at day 2 of EB
differentiation. Day 3.5 EBs were dissociated for downstream functional assays or
gene expression analysis. PRC1 inhibitor: PRT4165 (Tocris, cat# 5047), PRC2
inhibitor: UNC1999 (Tocris, cat# 4904) or the analogue UNC2400 (Tocris, cat#
4905).
Hydroxytamoxifen treatment of Rybpﬂ/ﬂ;Cre-ERT2 ES cells. Cells were treated
at day 2 of EB differentiation with 0.8 μM 4-hydroxytamoxifen (4-OHT) (Sigma,
H7904). Fresh media was added after 18–24 h. 4-OHT-treated EBs were allowed to
develop until day 3.5 when downstream assays were carried out.
Blast colony assay. 5 × 104 to 2 × 105 day 3.5 EB cells were seeded in 1%
methylcellulose IMDM medium, supplemented with 300 μg ml−1 transferrin
(Roche, cat# 10652202001), 25 μg ml−1 ascorbic acid (Sigma, A-4544), 4 × 10−4 M
MTG (1-Thiolglycerol, Sigma, M6145), 25% D4T (endothelial cell) conditioned
media, 5 ng/ml mouse VEGF, 5 ng ml−1 mouse interleukin 6 and 100 ng ml−1
mouse cKIT. Dishes were incubated in a humidiﬁed 5% CO2/air incubator and
colonies scored at day 460. All cytokines were purchased from Preprotech.
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Cardiac assay. Day 3.5 EB cells were replated at a density of 80,000 cells per
gelatin-coated 96-well plate, in StemPro34 serum-free medium supplemented with
100 U ml−1 penicillin, 100 μg ml−1 streptomycin (Gico/BRL), 2 mM glutamine
(Gibco/BRL), 10 ngml−1 human basic FGF, 12.5 ng ml−1 human FGF10, 5 ng ml−1
mouse VEGF and 1mM ascorbic acid (Sigma, A-4544)27. All growth factors were
purchased from R&D Systems. Medium was changed every other day until day 7,
when cultures were analysed.
Chondrogenic assay. After dissociation, single cell suspensions were seeded in
chondrogenic medium (alpha-MEM supplemented with 10% FBS, 1% penicillin/
streptomycin, 0.1 μM dexamethasone and 0.17 mM ascorbic-acid 2-phosphate) with
10 ngml−1 TGFβ3 for 6 days. On day 7, the medium was replaced with 10 ngml−1
BMP2. The culture was kept for another two weeks with a medium change every
3 days. On day 21, alcian blue staining was performed. Cells were ﬁxed with 4% PFA
for 30min, rinsed twice in PBS and once with water. Cultured cells were incubated
in 0.05% alcian blue solution, pH 1.5 (o/n, RT°)26. Presence of blue stained nodules
were inspected by microscopy and cultures imaged on a microscope (BX60;
Olympus) with a Q Imaging camera and OpenLab (Improvision) software.
Antibodies. References and conditions of use of all antibodies employed in this
study are shown in Supplementary Table 2.
Immunoﬂuorescence. Cells were ﬁxed in 4% PFA for 10mins on ice, washed three
times in PBS (5mins, RT°). They were then blocked and permeabilised in 0.2% Triton
X-100/PBS containing 10% donkey serum (Sigma, D9663), 1 h at RT°. Cells were
incubated with primary antibody in 0.2% Triton X-100/PBS containing 1% donkey
serum (o/n, 4 °C). After three washes of 5min at RT°, cells were incubated 1 h at RT°
with donkey-raised secondary antibody in 0.2% Triton X-100/PBS containing 1%
donkey serum and 0.5 μgml−1 DAPI. Cells were washed 3× in PBS for 5min and
visualised on Zeiss 880 inverted confocal microscope. Primary antibodies: cTNT
(Abcam, 1C11, 10 μgml−1), CD31 (R&D systems, AF3628, 2 μgml−1) and ColIIa
(DSHB, II-II6B3, 5 μgml−1). Secondary antibodies: Alexa-488 donkey anti-mouse
(A21202, 6 μgml−1), Alex-555 donkey anti-goat (Thermoﬁsher A-21432; 5 μgml−1).
Mice. All animal work was carried out under appropriate project licences
according to UK Home Ofﬁce regulations and approved by the Oxford University
Committee on Animal Care and Ethical Review. E9.5 embryos were harvested and
dissected to collect yolk sacs. Tissues were incubated in 0.125% collagenase (Sigma,
C0130) solution to achieve single cell suspensions (15 min, 37 °C). Each individual
yolk sac was replated in cardiac or chondrogenic medium on an OP9 layer.
Quantitative RT-PCR. Total RNA was extracted with Qiagen kits and DNase-
treated on column. 500 ng to 1 μg of total RNA was converted into cDNA using
Omniscript (Qiagen). For quantitative real-time expression analysis, qPCR reac-
tions were performed using TaqMan universal PCR mastermix (Life Technologies,
cat# 4304437) and TaqMan gene expression assays (Life Technologies). For Gapdh
and Gata1 genes, primers/probes were designed using Primer Express v3 software
and purchased from Eurogentec. References for all primers and probes used in
Taqman assays are shown in Supplementary Table 3. Expression levels were cal-
culated relative to a control sequence in the Gapdh gene. All reactions were per-
formed in duplicate using Sequence Detection System 7000 Thermocycler (Applied
Biosystems).
Immunoprecipitation (IP). EBs were dissociated and resuspended in Buffer A (10
mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, and proteinase inhibitors), kept
on ice for 10 min, and centrifuged for 10 s at 13,500 rpm. The nuclear pellet was
resuspended in 0.5% TritonX-100/RSB100 (10 mM Tris pH 8.0, 100 mM NaCl, 2.5
mM MgCl2, proteinase inhibitors), vortexed on/off for 30 min, kept on ice in
between. Extracts were rotated to release chromatin-bound SCL (5U Benzonase/1
μl extract for 1 h, 4 °C). Samples were centrifuged (4000 rpm, 15 min, 4 °C) and the
supernatant was treated with RNase A (100 μg ml−1, 2–3 min) before centrifuga-
tion (13,500 rpm, 1 min) to prevent RNA-mediated carryover. The supernatant
contained the soluble nuclear extracts. For IPs, nuclear extracts were precleared
with Protein G dynabeads for 30 min, before incubation with antibody pre-bound
to Protein G dynabeads for 3 h (SCL) or o/n (RING1B and RYBP). Beads were
washed 4× in 0.5% TritonX-100/RSB100 and eluted with 1xLDS (10 min, 70 °C).
Western blotting. Samples were run on a 4–12% precast Bis-tris gel, and trans-
ferred to a activated PVDF membrane (IPVH00010, Merck). The membrane was
blocked in 5% skimmed milk/PBS, and incubated in primary antibody 1 h in 5%
skimmed milk/PBS, washed four times in 0.05% tween/PBS, incubated in sec-
ondary antibody 1 h in 5% skimmed milk/PBS, washed as before and developed
with the ECL prime western blotting detection kit (RPN2232, GE healthcare Life
sciences). For histones, 106 cells were lysed in 20 mM Tris, pH 7.4, 20 mM EDTA,
pH 8, 2% SDS and 20% glycerol, boiled for 5 min and sonicated on Bioruptor Plus.
Semi-quantitation of the protein bands was performed using the Biorad Chemi doc
MP imaging system.
Uncropped scans are shown in Supplementary Figs. 8 and 9.
Flow cytometry and cell sorting. Cells were stained with PE-conjugated anti-
FLK1 and APC-conjugated anti-PDGFRα antibodies (eBioscience cat# 12-5821-83
and 17-1401-81) for 20 min at 4 °C, washed and sorted on BD FACS Aria II
(Becton Dickinson) or Sony SH800 FACS sorter.
SCL intracellular FACS. Cells were stained with live/dead stain kit (Thermoﬁsher,
L34955) for 20 min, ﬁxed in 2% PFA and permeabilised in 0.1% Triton X-100. Cells
were stained with anti-SCL antibody (Santa Cruz, clone C21) conjugated to Alexa-
488 (Zenon Alexaﬂuor-488 goat IgG labelling kit, Invitrogen, cat# Z25602) fol-
lowing manufacturer’s instructions.
cTNT intracellular FACS. Cardiac cultures were dissociated using 0.25% trypsin/
EDTA (Gibco/BRL) for 5 min at 37 °C to quickly lift the monolayer cells off the
plate, then a single cell suspension was achieved with a solution of collagenase/
DNase (PBS with 20% serum, 10 mgml−1 collagenase A (Roche,
cat#11088785103), 10 mgml−1 collagenase B and 10 μg ml−1 DNase I (Roche, cat#
1184932001), 5–10 min at 37 °C. Cells were stained with live/dead stain (Ther-
moﬁsher, cat# L34955) for 20 min, ﬁxed in 2% PFA and permeabilised in 0.5%
saponin (Sigma, cat# S7900). After a wash in PBS/0.1% saponin, cells were stained
with anti-cTNT (Abcam, clone 1C11) primary antibody and Alexa-488 donkey
anti-mouse (Thermoﬁsher, cat# A21202) secondary antibody.
Isolation of FLK1+ cells. Day 3.5/4 EB cells were stained with PE-conjugated FLK1
antibody (eBioscience) for 20 min. After a wash in PBS/FCS, cells were incubated
with anti-PE microbeads (Miltenyi) for 15 min. FLK1+ cells were isolated on
Myltenyi magnetic columns.
Single-cell RNA sequencing analysis. Single cell RNA-seq read-count tables
obtained from mouse embryos at different stages of development (days E6.5 to E7.75)
were downloaded from http://gastrulation.stemcells.cam.ac.uk/scialdone201614. The
data passed the quality control and cell ﬁltering processes described in the ref. 14. The
R-script for the t-distributed stochastic neighbour embedding (t-SNE) analysis of
different cell stages was kindly provided by A. Scialdone, and the ‘Rtsne’ function
from the Rtsne package with the input from highly variable genes was used (see
Method section in the ref. 14). To match day 3.5 EB cells to the distinct cell popu-
lations identiﬁed at different stages of mouse embryonic development, we selected 18
embryonic development-related genes highly expressed in day 3.5 EBs and super-
imposed the average gene expression of these genes (gene score) to visualise the
enrichment on the t-SNE plot.
RNAseq. WT and Scl−/− day 3.5 FLK1+ EB cells were isolated and total RNA
extracted. Library generation and sequencing were performed at Oxford Genomics
Centre (Wellcome Trust Centre of Human Genetics). Fastq reads were aligned to
the mm9 reference genome using tophat version 2.0.8b61. Duplicate read pairs were
removed, and reads ﬁltered for mapq > 15 using SAMtools version 0.1.1961. Data
normalisation and differential expression analysis was carried out using edgeR62.
Data normalisation to account for differences in sequencing depth and RNA
composition was performed using the TMM method (trimmed mean of M-
values63), provided by the edgeR package. Gene lists were analysed for biological
processes using PANTHER overrepresentation test64.
Chromatin immunoprecipitation (ChIP). For SCL, ETO2 and RYBP ChIP, 2–5 ×
107 day 3.5 (SCL) and day 4 (ETO2/RYBP) FLK1+ cells were ﬁxed 20 min, RT°
with 2 mM EGS (ethylene glycol bis succinimidylsuccinate, ThermoFisher Scien-
tiﬁc, cat# 10350924) followed by 1% Formaldehyde (Sigma, 252549) incubation for
10 min under gentle agitation before quenching with 0.125 M glycine. Cells were
rinsed twice with PBS, lysed, and chromatin sonicated to an average size of 300
base pairs using Bioruptor Plus (Diagenode) at Power 3.0 for 17 cycles (30 s ON,
30 s OFF). The resulting chromatin was diluted 10× in ChIP dilution buffer and 1%
put aside as input sample. After pre-clearing with protein A/G dynabeads (Ther-
moFisher Scientiﬁc), supernatants were incubated with appropriate antibodies o/n.
Beads were washed in low salt/high salt LiCl buffers and twice with Tris/EDTA.
Complexes were eluted from beads in a thermomixer (65 °C, 15 min) and eluates
and reserved inputs reverse cross-linked (65 °C, o/n). Samples were treated with
RNaseA, proteinase K and phenol/chloroform-puriﬁed.
ChIP-sequencing. ChIP samples were submitted to library preparation using
NEBNext Ultra DNA Library prep kit and multiplexing barcodes (NEB, E7370)
following Illumina’s instructions. Samples were quantiﬁed by the KAPA Library
Quantiﬁcation Kit (Roche diagnostics, cat# 7960140001) and their sizes veriﬁed on
a Bioanalyser 2100 (Agilent). Libraries were sequenced using NextSeq v2 kit (75
cycles, Illumina, FC-404-2005) on a NextSeq 550 system with paired-end reads for
37 cycles. Sequences were de-multiplexed, aligned to the Mus musculus (mm9)
genome using Bowtie (version 1.1.2), and ﬁltered to remove duplicate mapped
reads. Peak calling was performed with MACS2 (version 2.0.10) using default
parameters for SCL and ETO2 ChIP; the broad option was applied for RYBP ChIP.
MIG (Multi-Image Genome viewer) was used to visualise the data, ﬁlter and
identify peaks65. Data for heatmaps and meta gene plots were generated using
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HOMER annotatePeaks command and visualised with Java_Treeview. GO analysis
of genomic regions was performed with Stanford GREAT online tool66. The
ATAC-seq procedure and data will be reported somewhere else.
Histone ChIP-sequencing-Rx. Histone ChIPSeq-Rx was carried out according to
published protocols37. Brieﬂy, day 4 mCherry-positive sorted cells were mixed in a
2:1 ratio to Drosophila S2 cells. Samples were prepared and sequencing was per-
formed as above. Data were mapped using an in-house pipeline. Reads were
aligned to Mus musculus (mm9) and Drosophila melanogaster (dm3) genomes.
The number of reads mapping to the genomes as well as the derived normalisation
factor for each histone mark are provided in Supplementary Data 4. Peak calling
was performed using MACS2 (version 2.0.10) using parameters for broad peak
calling and respective inputs as reference. Tag directories were created using
Homer and the generated BedGraphs were visualised on UCSC Genome Browser
as custom tracks, after scaling the tag densities by the normalisation factor for each
histone mark. Histograms and heatmaps were generated using AnnotatePeaks.pl
command with up to −100 kb to 100 kb around the indicated genomic regions
separated into 25 equally sized bin; the ChIP fragment coverage was scaled by the
derived normalisation factor.
Code availability. All codes used in this study can be accessed from the GEO
database (accession number GSE104883).
Data availability
All ChIP-seq and RNA-seq datasets are deposited at the NCBI GEO database
under the accession number GSE104883. All other data supporting the results of
this study are available within the article and its supplementary information ﬁles
and from the corresponding author upon request. A reporting summary is
available as a Supplementary Information ﬁle.
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